Medicare受益人中低密度脂蛋白胆固醇降低疗法的使用与费用趋势
该横断面研究分析2014至2018年Medicare Part D数据,覆盖11种LDL-C降低药物。PCSK9抑制剂使用量增长144%但基数仍小。
要点
- LDL-C降低疗法使用人数增加23%,总支出下降46%。
- PCSK9抑制剂使用增长144%,支出增长199%,未来影响需关注。
研究设计与样本
- 横断面研究,分析2014至2018年Medicare Part D处方药事件数据,纳入11种LDL-C降低药物(25种剂型,16品牌和9仿制)。
临床怎么用
- 优先使用仿制他汀和依折麦布可显著降低Medicare支出。
- PCSK9抑制剂使用虽增长但基数仍小,需关注其对未来支出的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C)-lowering therapies are a cornerstone of prevention in atherosclerotic cardiovascular disease. With the introduction of generic formulations and the release of new therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, contemporary Medicare utilization of these therapies remains unknown. OBJECTIVE: To determine trends in utilization and spending on brand-name and generic LDL-C-lowering therapies and to estimate potential savings if all Medicare beneficiaries were switched to available therapeutically equivalent generic formulations. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study analyzed prescription drug utilization and cost trend data from the Medicare Part D Prescription Drug Event data set from 2014 to 2018 for LDL-C-lowering therapies. A total of 11 LDL-C-lowering drugs with 25 formulations, including 16 brand-name and 9 generic formulations, were included. Data were collected and analyzed from October 2019 to June 2020. MAIN OUTCOMES AND MEASURES: Number of Medicare Part D beneficiaries, annual spending, and spending per beneficiary for all formulations. RESULTS: The total number of Medicare Part D beneficiaries ranged from 37 720 840 in 2014 to 44 249 461 in 2018. The number of Medicare beneficiaries taking LDL-C-lowering therapies increased by 23% (from 20.5 million in 2014 to 25.2 million in 2018), while the associated Medicare expenditure decreased by 46% (from $6.3 billion in 2014 to $3.3 billion in 2018). Lower expenditure was driven by greater uptake of generic statin and ezetimibe and a concurrent rapid decline in the use of their brand-name formulations. Medicare spent $9.6 billion on brand-name statins and ezetimibe and could have saved $2.1 billion and $0.4 billion, respectively, if brand-name formulations were switched to equivalent generic versions when available. The number of beneficiaries using PCSK9 inhibitors since their introduction in 2015 has been modest, although use has increased by 144% (from 25 569 in 2016 to 62 476 in 2018) and total spending has increased by 199% (from $164 million in 2016 to $491 million in 2018). CONCLUSIONS AND RELEVANCE: Between 2014 and 2018, LDL-C-lowering therapies were used by 4.8 million more Medicare beneficiaries annually, with an associated $3.0 billion decline in Medicare spending. This cost reduction was driven by the rapid transition from brand-name formulations to lower-cost generic formulations of statins and ezetimibe. Use of PCSK9 inhibitions, although low, increased over time and could have broad implications on future Medicare spending.
引用
- Sumarsono A, Lalani HS, Vaduganathan M, et al. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. JAMA Cardiol. 2021. PMID: 32902560. doi:10.1001/jamacardio.2020.3723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。